Clinical TrialJul 2, 2026, 07:02 AM
Tenax Therapeutics to Present LEVEL Trial Results at ESC 2026
AI Summary
Tenax Therapeutics announced that results from its Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, held from August 28-31 in Munich, Germany. The company anticipates reporting topline data from the LEVEL trial in August 2026, ahead of the presentation. The LEVEL trial evaluates TNX-103 (oral levosimendan) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
Key Highlights
- Phase 3 LEVEL clinical trial results to be presented at ESC Congress 2026.
- Presentation by Professor Sanjiv Shah on August 29, 2026, in Munich, Germany.
- Company expects to report topline LEVEL trial data in August 2026.
- LEVEL trial evaluates TNX-103 (oral levosimendan) for PH-HFpEF.
- Enrollment of over 230 patients completed in March 2026.
- Trial powered at over 90% for 25-meter change in 6-minute walk distance.
Price Impact
More from TENX